ABVC BioPharma (ABVC) 10-Q/A 22 May 17 2017 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2016	Feb. 14, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	American BriVision (Holding) Corp
Entity Central Index Key	1,173,313
Trading Symbol	mtoo
Amendment Description	Explanatory Note American BriVision (Holding) Corporation (together with its subsidiary, the “Company” sometimes referred to as “we”, “us” or “our”) is filing this Amendment No. 1 (this “Amendment No.1” or “Form 10-Q/A”) to its Quarterly Report on Form 10-Q for the period ended December 31, 2016, originally filed on February 21, 2017, (the “Original Form 10-Q”) to reflect the restatement of its consolidated financial statements for the period ended December 31, 2016, and related disclosures described below. The restatement of the Original Form 10-Q reflected in this Amendment corrects the carryover typographical errors principally related to additional paid-in capital, accumulated deficit as of December 31, 2016 and disclosure of earning per shares for the three-months ended December 31, 2016 and 2015. There is no impact or changes to the consolidated statement of operations and cash flow for the three months ended December 31, 2016 and 2015; and to the total assets, total liability and total stockholders’ equity as of December 31, 2016 and September 30, 2016. For details of the changes, please refer to Note 2 of the consolidated financial statements. No other sections were affected, but for the convenience of the reader, this report on Form 10-Q/A Amendment No.1 restates in its entirety, as amended, our Original Form 10-Q. This report on Form 10- Q/A Amendment No.1 is presented as of the filing date of the Original Form 10-Q and does not reflect events occurring subsequent to the date of filing of the Original Form 10-Q. Background of Restatements in Amendment No.1 The additional paid-in capital and accumulated deficit as of December 31, 2016 was erroneously stated as $4,733,401 and $(11,463,678), respectively on the Original Form 10-Q. The Company restated the additional paid-in capital and accumulated deficit as of December 31, 2016 as $4,733,461 and $(11,463,738), respectively. The typographical error caused $60 difference in both accounts. There is no impact on the ending balance of the total stockholders’ equity as of December 31, 2016. On the Notes 8 to Consolidated Financial Statements of the Original Form 10-Q, the net loss and weight-average shares outstanding basic and diluted included in the disclosure of the earning per share for the three-months ended December 31, 2016 was erroneously reflected as (11,065,935) and 193,981,153, respectively. The earning-per-share on the Original Form 10-Q for the three-months ended December 31, 2016 was (0.06). The Company corrected the net loss and weight-average shares outstanding basic and diluted included in the disclosure of the earning per share for the three-months ended December 31, 2016 to (140,337) and 210,821,647, respectively in order to align with the net loss and weight-average shares outstanding basic and diluted as reflected on the accompanying unaudited Condensed Consolidated Statements of Operations for the three months ended December 31, 2016. The corrected earning per share was $0.00. The overall impact in the earning-per-share for the three months ended December 31, 2016 is $0.06. On the Notes 8 to Consolidated Financial Statements of the Original Form 10-Q, the net loss and weight-average shares outstanding basic and diluted included in the disclosure of the earning per share for the three-months ended December 31, 2015 was erroneously reflected as (317,015) and 160,823,831, respectively. The earning-per-share on the Original Form 10-Q for the three-months ended December 31, 2015 was (0.00). The Company corrected the net loss and weight-average shares outstanding basic and diluted included in the disclosure of the earning per share for the three-months ended December 31, 2015 to (3,501,413) and 163,881,199, respectively in order to align with the net loss and weight-average shares outstanding basic and diluted as reflected on the accompanying unaudited Condensed Consolidated Statements of Operations for the Three Months Ended December 31, 2015. The corrected earning per share was $(0.02). The overall impact in the earning-per-share for the three months ended December 31, 2015 is $(0.02) Items Amended by the Amendment No.1 This Amendment reflects the results of the work described above and includes the restatement of our consolidated financial statements for the period ended December 31, 2016. For the convenience of the reader, this Amendment sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the restatement and other related adjustments, internal control matters, and as otherwise specifically indicated. Specifically, the following items included in the Original Form 10-Q are amended by this Amendment: - Part I, Item 1, Financial Statements - Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operation
Amendment Flag	true
Current Fiscal Year End Date	--09-30
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		210,821,647

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Current assets
Cash	$ 18,645	$ 173,537
Total Current Assets	18,645	173,537
Deposit		3,815
Total Assets	18,645	177,352
Liabilities and Equity
Accounts Payable		18,370
Accrued expense	38,100	38,100
Due to related party	6,500,000	6,500,000
Total Liabilities	6,538,100	6,556,470
Commitments and Contingencies
Stockholders' equity
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 210,821,647 at December 31, 2016 and September 30, 2016	210,822	210,822
Additional paid-in capital	4,733,461	4,733,461
Subscription receivable
Accumulated deficit	(11,463,738)	(11,323,401)
Total equity	(6,519,455)	(6,379,118)
Total liabilities and equity	$ 18,645	$ 177,352

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Dec. 31, 2016	Sep. 30, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	360,000,000	360,000,000
Common stock, shares issued	210,821,647	210,821,647
Common stock, shares outstanding	210,821,647	210,821,647

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues	$ 70,000
Cost of sales
Gross profit	70,000
Operating expenses
Selling, general and administrative expenses	185,188	1,605
Research and Development	25,198	3,500,000
Total Operating Expenses	210,386	3,501,605
Net loss from operations	(140,386)	(3,501,605)
Other income (expense)
Bank Interest Income	49	103
Gain on exchange differences		89
Total Other Income	49	192
Loss from continuing operations before income taxes	(140,337)	(3,501,413)
Income taxes
Net loss	$ (140,337)	$ (3,501,413)
Basic and Diluted loss per share
Basic and diluted loss per share	$ 0	$ (0.02)
Weighted average number of shares outstanding basic and diluted	210,821,647	163,881,199

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss from continuing operations	$ (140,337)	$ (3,501,413)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase (decrease) in deposit	3,815
Increase (decrease) in accounts receivable		(550,349)
(Increase) decrease in accounts payable		(300,000)
Increase (decrease) in due to related party		3,477,483
Increase (decrease) in accounts payable	(18,370)
Net cash used in operating activities	(154,892)	(874,279)
Cash flows from investing activities
Net cash provided (used) by investing activities
Cash flows from financing activities
(Decrease) increase in due to shareholder		350,000
(Decrease) increase in due to shareholder		(46,586)
Net cash provided (used) by financing activities		303,414
Net increase (decrease) in cash	(154,892)	(570,865)
Cash, beginning of period	173,537	994,830
Cash, end of period	18,645	423,965
Supplemental disclosure of cash flow information
Interest paid
Income taxes paid

Organization and Description of

Organization and Description of Business	3 Months Ended
	Dec. 31, 2016
Organization and Description of Business [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, thru the Company’s operating entity, American BriVision Corporation (“BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. REVERSE MERGER On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People Republic of China (“Euro-Asia”), being the owners of record of 52,336,000 shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 52,936,583 shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 51,945,225 shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock. Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. Accounting Treatment of the Reverse Merger For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

Corrections to Previously Issue

Corrections to Previously Issued Consolidated Financial Statements	3 Months Ended
	Dec. 31, 2016
Corrections to Previously Issued Consolidated Financial Statements [Abstract]
CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	2. CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS The Company discovered that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement: 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016). It had erroneously stated that the research and development expenses were $0 and $0 for the three and six months ended March 31, 2016. Instead, our research and development expenses were $6,500,000 and $10,000,000 for the three and six months ended March 31, 2016. The Company restated the consolidated financial statements for December 31, 2016 as a consequence of the carryover changes from the year ended September 30, 2016. The item Additional paid-in-capital adjusted up with $60 while the Accumulated deficit adjusted down with ($60). The change of the following items offset each other and no other items in the consolidated balance sheet have been changed. ITEMS As of and for the Period Ended Previously Adjustments Restated Consolidated Balance Sheets Additional paid-in-capital 4,733,401 60 4,733,461 Accumulated deficit (11,463,678 ) (60 ) (11,463,738 ) The Company discovered that it had erroneously stated that the research and development expenses were understated during the year ended September 30, 2016. Corrections had been made and there were some changes in the liabilities and shareholders’ equity item of the consolidated balance sheet. The following tables present the effect of the corrections discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of September 30, 2016, ITEMS As of and for the Year Ended Previously Adjustments Restated Consolidated Balance Sheet As of September 30, 2016 Due to related party - 6,500,000 6,500,000 Total Liabilities 56,470 6,500,000 6,556,470 Additional paid-in capital 4,733,401 60 4,733,461 Accumulated deficit (4,823,401 ) (6,500,000 ) (11,323,401 ) Total equity (deficit) 120,882 (6,500,000 ) (6,379,118 ) As a result of the restatement of the consolidated balance sheets as of September 30, 2016, Due to related party and Total liabilities were increased by $6,500,000; changed from $0 to $6,500,000 and from $56,470 to $6,556,470. Additional paid in capital was increased by $60 and changed from $4,733,401 to $4,733,461. Accumulated deficit was increased by $6,500,000 and changed from $(4,823,401) to $(11,323,401). Total equity/(deficit) was decreased by $6,500,000 and changed from $120,882 to $(6,379,118).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting. Consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars. The condensed financial statements include all adjustments that, in the opinion of management, are necessary in order not to make the financial statements misleading. Certain information and footnote disclosure normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The results of operations for the periods ended December 31, 2016 are not necessarily indicative of the operating results for the full year. Basis of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiary, American BriVision Corporation ("BriVision"). All intercompany transactions, balances and any unrealized profit and losses have been eliminated on consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results. Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of December 31, 2016. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2016, the Company’s cash and cash equivalents amounted $18,645. As of September 31, 2016, the Company’s cash and cash equivalents amounted $173,537. All of the Company’s cash deposits are held in a financial institution located in PRC where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality. Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred. Stock-based Compensation The Company measures expense associated with all employee share-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation” The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 ”Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Stock-based compensation expenses were recorded in general and administrative expenses and research and development expenses. Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to December 31, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As of December 31, 2016 and December 31, 2015, the Company’s income tax expense amounted $0 and $0, respectively. Earnings Per Share of Common Stock The Company reports earnings (loss) per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Commitments and Contingencies The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred. Recent Accounting Pronouncements From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.

Going Concern

Going Concern	3 Months Ended
	Dec. 31, 2016
Going Concern [Abstract]
GOING CONCERN	4. GOING CONCERN The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $11,463,738 as of December 31, 2016. The Company also incurred net losses of $140,337 and negative cash flow of $154,892 during the three months ended December 31, 2016. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These combined financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the Collaborative Agreement, 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. $6,500,000 was wholly recorded as due to related party as of December 31, 2016 This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. The Company determined to fully expense the entire amount of $3,500,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense.

Collaborative Agreement

Collaborative Agreement	3 Months Ended
	Dec. 31, 2016
Collaborative Agreement [Abstract]
COLLABORATIVE AGREEMENT	5. COLLABORATIVE AGREEMENT On December 29, 2015, American BriVision Corporation entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. Under the Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule: ● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. Pursuant to the Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the Collaborative Agreement,6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. $6,500,000 was wholly recorded as accounts payable as of December 31, 2016. This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and

Related Parties Transactions

Related Parties Transactions	3 Months Ended
	Dec. 31, 2016
Related Parties Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	5. RELATED PARTIES TRANSACTIONS During the quarter ended December 31, 2016, the Company recorded revenue of $70,000 for a consulting service provided to a Company’s shareholder, Liongene Corporation. As of December 31, 2016 and September 30, 2016, the amount due to a related party, BioLite, Inc (“Biolite”) was $6,500,000 and $6,500,000 respectively.

Accounts Payable

Accounts Payable	3 Months Ended
	Dec. 31, 2016
Accounts Payable [Abstract]
ACCOUNTS PAYABLE	7. ACCOUNTS PAYABLE As of December 31, 2016 and September 30, 2016, the amount Accounts Payable to LiteArt, Inc. was $0 and $18,370 respectively.

Equity

Equity	3 Months Ended
	Dec. 31, 2016
Equity [Abstract]
EQUITY	8. EQUITY During October 2015, $350,000 of subscription receivable was fully collected from the shareholders. On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921 (52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees. On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to affect a forward split at a ratio of 1 to 3.141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares (“Shares”) of the Company’s common stock, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. Our sole director, Eugene Jiang, is a director of BioLite and it is therefore considered a related party. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
EARNINGS PER SHARE	9. EARNINGS PER SHARE Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year. For the Three Months Ended For the Three Months Ended (Restated) Numerator: Net loss $ (140,337 ) (3,501,413 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic 210,821,647 163,881,199 Stock options - - Weighted-average shares outstanding - Diluted 210,821,647 163,881,199 Earnings per share -Basic (0.00 ) (0.02 ) -Diluted (0.00 ) (0.02 ) Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES Operating Commitment The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of December 31, 2016 are payable as follows: Year ending September 30, 2017 23,793 Year ending September 30, 2018 17,845 Total $ 41,638 Rental expenses of the company was $14,330 and nil for the three months ended December 31, 2016 and 2015.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting. Consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars. The condensed financial statements include all adjustments that, in the opinion of management, are necessary in order not to make the financial statements misleading. Certain information and footnote disclosure normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The results of operations for the periods ended December 31, 2016 are not necessarily indicative of the operating results for the full year.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiary, American BriVision Corporation ("BriVision"). All intercompany transactions, balances and any unrealized profit and losses have been eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.
Forward Stock split	Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.
Fair Value Measurements	Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of December 31, 2016.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2016, the Company’s cash and cash equivalents amounted $18,645. As of September 31, 2016, the Company’s cash and cash equivalents amounted $173,537. All of the Company’s cash deposits are held in a financial institution located in PRC where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.
Research and Development Expenses	Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.
Stock-based Compensation	Stock-based Compensation The Company measures expense associated with all employee share-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation” The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 ”Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Stock-based compensation expenses were recorded in general and administrative expenses and research and development expenses.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to December 31, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As of December 31, 2016 and December 31, 2015, the Company’s income tax expense amounted $0 and $0, respectively.
Earnings Per Share of Common Stock	Earnings Per Share of Common Stock The Company reports earnings (loss) per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.
Commitments and Contingencies	Commitments and Contingencies The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The recent accounting standards are not expected to have a material impact on the consolidated financial statements upon adoption.

Corrections to Previously Iss17

Corrections to Previously Issued Consolidated Financial Statements (Tables)	3 Months Ended
	Dec. 31, 2016
Corrections to Previously Issued Consolidated Financial Statements [Abstract]
Schedule of corrections and consolidated financial statements	ITEMS As of and for the Period Ended Previously Adjustments Restated Consolidated Balance Sheets Additional paid-in-capital 4,733,401 60 4,733,461 Accumulated deficit (11,463,678 ) (60 ) (11,463,738 ) ITEMS As of and for the Year Ended Previously Adjustments Restated Consolidated Balance Sheet As of September 30, 2016 Due to related party - 6,500,000 6,500,000 Total Liabilities 56,470 6,500,000 6,556,470 Additional paid-in capital 4,733,401 60 4,733,461 Accumulated deficit (4,823,401 ) (6,500,000 ) (11,323,401 ) Total equity (deficit) 120,882 (6,500,000 ) (6,379,118 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of earnings per share	For the Three Months Ended For the Three Months Ended (Restated) Numerator: Net loss $ (140,337 ) (3,501,413 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic 210,821,647 163,881,199 Stock options - - Weighted-average shares outstanding - Diluted 210,821,647 163,881,199 Earnings per share -Basic (0.00 ) (0.02 ) -Diluted (0.00 ) (0.02 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Schedule of future minimum lease payments	Year ending September 30, 2017 23,793 Year ending September 30, 2018 17,845 Total $ 41,638

Organization and Description 20

Organization and Description of Business (Details)	Feb. 08, 2016shares
Share Exchange Agreement [Member]
Organization and Description of Business (Textual)
Common stock issued pre-stock split	52,336,000
Share Exchange Agreement 2 [Member]
Organization and Description of Business (Textual)
Common stock issued pre-stock split	51,945,225
Percentage of common shares issued and outstanding	79.70%
Percentage of issued share capital	100.00%
Share Exchange Agreement 3 [Member]
Organization and Description of Business (Textual)
Common stock issued pre-stock split	52,936,583
Share Exchange Agreement 4 [Member]
Organization and Description of Business (Textual)
Common stock issued pre-stock split	65,431,144
Percentage of common shares issued and outstanding	79.70%

Corrections to Previously Iss21

Corrections to Previously Issued Consolidated Financial Statements (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Consolidated Balance Sheet
Due to related party	$ 6,500,000	$ 6,500,000
Total Liabilities	6,538,100	6,556,470
Additional paid-in-capital	4,733,461	4,733,461
Accumulated deficit	(11,463,738)	(11,323,401)
Total equity (deficit)	(6,519,455)	(6,379,118)
Previously Reported [Member]
Consolidated Balance Sheet
Due to related party
Total Liabilities		56,470
Additional paid-in-capital	4,733,401	4,733,401
Accumulated deficit	(11,463,678)	(4,823,401)
Total equity (deficit)		120,882
Restated [Member]
Consolidated Balance Sheet
Due to related party		6,500,000
Total Liabilities		6,556,470
Additional paid-in-capital	4,733,461	4,733,461
Accumulated deficit	(11,463,738)	(11,323,401)
Total equity (deficit)		(6,379,118)
Adjustments [Member]
Consolidated Balance Sheet
Due to related party		6,500,000
Total Liabilities		6,500,000
Additional paid-in-capital	60	60
Accumulated deficit	$ (60)	(6,500,000)
Total equity (deficit)		$ (6,500,000)

Corrections to Previously Iss22

Corrections to Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended			6 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Sep. 30, 2016
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Collaborative agreement, Description	Company discovered that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement: 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016).
Research and development expenses	$ 25,198		$ 3,500,000
Additional paid in capital	4,733,461				$ 4,733,461
Accumulated deficit	(11,463,738)				(11,323,401)
Due to related party	6,500,000				6,500,000
Total liabilities	6,538,100				6,556,470
Total equity (deficit)	(6,519,455)				(6,379,118)
Previously Reported [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Research and development expenses		$ 0		$ 0
Additional paid in capital	4,733,401				4,733,401
Accumulated deficit	(11,463,678)				(4,823,401)
Due to related party
Total liabilities					56,470
Total equity (deficit)					120,882
Restated [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Research and development expenses		$ 6,500,000		$ 10,000,000
Additional paid in capital	4,733,461				4,733,461
Accumulated deficit	(11,463,738)				(11,323,401)
Due to related party					6,500,000
Total liabilities					6,556,470
Total equity (deficit)					(6,379,118)
Adjustments [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Additional paid in capital	60				60
Accumulated deficit	$ (60)				(6,500,000)
Due to related party					6,500,000
Total liabilities					6,500,000
Total equity (deficit)					$ (6,500,000)

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 21, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Summary of Significant Accounting Policies (Textual)
Forward split ratio	1 to 3.141
Common stock, par value	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized	360,000,000	360,000,000		360,000,000
Cash and cash equivalents amounted		$ 18,645	$ 423,965	$ 173,537	$ 994,830
Income tax expense

Going Concern (Details)

Going Concern (Details) - USD ($)	May 06, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016	Dec. 29, 2015
Going Concern (Textual)
Accumulated deficit		$ (11,463,738)		$ (11,323,401)
Net loss for the period		(140,337)	$ (3,501,413)
Negative cash flow		(154,892)	$ (570,865)
Due to related party		6,500,000		$ 6,500,000
Collaborative Agreement [Member]
Going Concern (Textual)
Milestone payments to BioLite in cash	$ 2,600,000
Common stock newly issued, value	$ 900,000
Issuance of common shares, shares	562,500
Share price	$ 1.60
Due to related party		$ 6,500,000			$ 100,000,000
Percentage of payments under collaborative agreement		3.50%
Licensing rights		$ 3,500,000
Collaborative Agreement One [Member]
Going Concern (Textual)
Percentage of payments under collaborative agreement		6.50%
Licensing rights		$ 6,500,000

Collaborative Agreement (Detail

Collaborative Agreement (Details) - USD ($)	May 06, 2016	Dec. 31, 2016	Sep. 30, 2016	Dec. 29, 2015
Collaborative Agreement (Textual)
Amount received from BriVision		$ 6,500,000	$ 6,500,000
Accounts payable			18,370
Collaborative Agreement [Member]
Collaborative Agreement (Textual)
Description of payment settlement schedule		● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
Amount received from BriVision		$ 6,500,000		$ 100,000,000
Upfront payments			$ 3,500,000
Milestone payments to BioLite in cash	$ 2,600,000
Common stock newly issued, value	$ 900,000
Common stock newly issued, shares	562,500
Share price	$ 1.60
Licensing rights		3,500,000
Accounts payable		$ 6,500,000
Percentage of payments under collaborative agreement		3.50%
Collaborative Arrangement One [Member]
Collaborative Agreement (Textual)
Description of payment settlement schedule		Pursuant to the Collaborative Agreement,6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. $6,500,000 was wholly recorded as accounts payable as of December 31, 2016.
Licensing rights		$ 6,500,000
Percentage of payments under collaborative agreement		6.50%

Related Parties Transactions (D

Related Parties Transactions (Details) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Related Parties Transactions (Textual)
Amount received from BriVision	$ 6,500,000		$ 6,500,000
Revenues	$ 70,000

Accounts Payable (Details)

Accounts Payable (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Accounts Payable (Textual)
Accounts payable to LiteArt, Inc.		$ 18,370

Equity (Details)

Equity (Details) - USD ($)	May 06, 2016	Mar. 21, 2016	Feb. 08, 2016	Aug. 26, 2016	Feb. 17, 2016	Dec. 31, 2016	Sep. 30, 2016	Oct. 31, 2015
Equity (Textual)
Common stock, shares authorized		360,000,000				360,000,000	360,000,000
Common stock, par value		$ 0.001				$ 0.001	$ 0.001
Description of forward split		1 to 3.141
Subscription receivable								$ 350,000
2016 Plan [Member]
Equity (Textual)
Common stock issued pre-stock split					50,000
Common stock issued post-stock split					157,050
Biolite Inc [Member]
Equity (Textual)
Common stock, par value				$ 0.001
Issuance of common shares				$ 1,468,750
Purchase price per share				$ 1.60
Net proceeds from offering				$ 2,350,000
Share Exchange Agreement [Member]
Equity (Textual)
Common stock issued pre-stock split			52,336,000
Common stock issued post-stock split			164,387,376
Share Exchange Agreement 2 [Member]
Equity (Textual)
Common stock issued pre-stock split			51,945,225
Common stock issued post-stock split			163,159,952
Percentage of common shares issued and outstanding			79.70%
Percentage of issued share capital			100.00%
Share Exchange Agreement 3 [Member]
Equity (Textual)
Common stock issued pre-stock split			52,936,583
Common stock issued post-stock split			166,273,921
Exchange ratio			0.2536-for-1
Share Exchange Agreement 4 [Member]
Equity (Textual)
Common stock issued pre-stock split			65,431,144
Common stock issued post-stock split			205,519,223
Percentage of common shares issued and outstanding			79.70%
Collaborative Arrangement [Member]
Equity (Textual)
Issuance of common shares	$ 900,000
Stock issued during period, Shares, New issues	562,500
Share price	$ 1.60

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net loss	$ (140,337)	$ (3,501,413)
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic	210,821,647	163,881,199
Stock options
Weighted-average shares outstanding - Diluted	210,821,647	163,881,199
Earnings per share
-Basic	$ 0	$ (0.02)
-Diluted	$ 0	$ (0.02)

Commitments and Contingencies30

Commitments and Contingencies (Details)	Dec. 31, 2016USD ($)
Future minimum lease payment [Abstract]
Year ending September 30, 2017	$ 23,793
Year ending September 30, 2018	17,845
Total	$ 41,638

Commitments and Contingencies31

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies (Textual)
Rental expenses	$ 14,330